EuroPCR 2018 | SYNTAX II: Results at 2 Years for Best Angioplasty vs. Surgery in Multivessel Disease

Since the publication of the original SYNTAX trial, there have been great technical advancements that have influenced the results of angioplasty:

  • New tools for risk stratification using the SYNTAX II score which integrate clinical and anatomical variables to the team’s decision-making process.
  • Functional revascularization (hybrid use of fractional flow reserve or instantaneous wave-free ratio).
  • Optimization of stenting through intravascular ultrasound.
  • Contemporary techniques for the rechanneling of total occlusions.
  • Clinical therapies according to guidelines.
  • New thin-strut bioresorbable-polymer everolimus-eluting stents.

EuroPCR 2018 | SYNTAX II: resultados a 2 años de la mejor angioplastia vs cirugía en múltiples vasosThis was a single-arm study in patients with multivessel disease on the impact of these new technologies on 450 patients who were compared with the original SYNTAX cohort and were selected based on similar mortality rates at 4 years. The study also carried out an exploratory comparison of this cohort and the historical cohort that underwent surgery.

 

At 2 years, the 454 patients in the SINTAX II cohort experienced significantly less events than the historical cohort (major adverse cardiac or cerebrovascular events [MACCE]: 10.7% for SYNTAX II patients vs. 17.4% for SYNTAX patients; hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.40-0.86; p = 0.007). Such difference was driven by lower rates of both infarction (HR: 0.27; 95% CI: 0.11-0.70; p = 0.007) and revascularization (HR: 0.57; 95% CI: 0.37-0.89; p = 0.014).


Read also: EuroPCR 2018 | Compare-Acute: FFR or Primary Angioplasty at a 2-Year Follow-Up After Complete Revascularization.


The rates of mortality and stroke were similar. The rates of definite stent thrombosis were significantly lower with the new strategy (HR: 0.26; 95% CI: 0.07-0.97; p = 0.045).

 

The exploratory comparison with myocardial revascularization surgery suggests equivalent results for the SYNTAX II strategy in patients with a >22 score, not only in patients with low anatomical risk.

 

Original title: SYNTAX II: Two-Year Clinical Outcomes of the Study Using State-of-the-Art Percutaneous Coronary Revascularisation in Patients with De Novo Three-Vessel Disease.

Presenter:  Patrick W. Serruys.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...